Literature DB >> 26474544

Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.

Donatella Aldinucci1, Marta Celegato2, Naike Casagrande2.   

Abstract

Classical Hodgkin lymphoma (cHL) is characterized by few tumor cells surrounded by immune cells, fibroblasts, specialized mesenchymal stromal cells and endothelial cells, representing together with their products an active part of the disease. Hodgkin and Reed-Sternberg (HRS) cells can secrete cytokines/chemokines and angiogenic factors capable of recruiting and/or inducing the proliferation of the surrounding cells and can also interact with distant sites of the microenvironment by secreting exosomes. To escape from a useful anti-tumor response due to the recognition by T and NK cells, HRS cells down-regulate HLA molecules, produce immune suppressive cytokines that inhibit cytotoxic responses, and induce an immunosuppressive phenotype on T lymphocytes and Monocytes. HRS cells survive, proliferate and are protected from the cytotoxic effects of chemotherapy agents by soluble factors or by the direct contact with inflammatory and stromal cells of the tumor microenvironment (TME). A summary of the current knowledge about classical Hodgkin Lymphoma focusing on the cross-talk between tumor cells and the microenvironment leading to immune-escape, angiogenesis tumor growth/survival and drug resistance will be reviewed here.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Drug-resistance; Hodgkin lymphoma; Immune-escape; Tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 26474544     DOI: 10.1016/j.canlet.2015.10.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  35 in total

1.  Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.

Authors:  Alex Reza Gholiha; Peter Hollander; Ingrid Glimelius; Gustaf Hedstrom; Daniel Molin; Henrik Hjalgrim; Karin E Smedby; Jamileh Hashemi; Rose-Marie Amini; Gunilla Enblad
Journal:  Blood Adv       Date:  2021-03-23

2.  CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth.

Authors:  Sakthi Rajendran; Weng Tong Ho; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

3.  Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas.

Authors:  Mikael Roussel; Faustine Lhomme; Caroline E Roe; Todd Bartkowiak; Pauline Gravelle; Camille Laurent; Thierry Fest; Jonathan M Irish
Journal:  Cancer Immunol Immunother       Date:  2020-01-09       Impact factor: 6.968

Review 4.  Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.

Authors:  Michael D Jain; John Kuruvilla
Journal:  Drugs       Date:  2017-10       Impact factor: 11.431

5.  CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.

Authors:  Hinrich P Hansen; Ahmad Trad; Maria Dams; Paola Zigrino; Marcia Moss; Maximilian Tator; Gisela Schön; Patricia C Grenzi; Daniel Bachurski; Bruno Aquino; Horst Dürkop; Katrin S Reiners; Michael von Bergwelt-Baildon; Michael Hallek; Joachim Grötzinger; Andreas Engert; Adriana F Paes Leme; Elke Pogge von Strandmann
Journal:  Oncotarget       Date:  2016-05-24

6.  Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.

Authors:  Zhixing Kuang; Li Guo; Xun Li
Journal:  Mol Med Rep       Date:  2017-08-03       Impact factor: 2.952

7.  Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.

Authors:  Cinzia Borghese; Naike Casagrande; Eliana Pivetta; Alfonso Colombatti; Mariarosaria Boccellino; Evzen Amler; Nicola Normanno; Michele Caraglia; Giuseppe De Rosa; Donatella Aldinucci
Journal:  Oncotarget       Date:  2017-06-27

8.  Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity.

Authors:  Wan-Peng Wang; Hai-Ying Gao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

Review 9.  Brentuximab vedotin: clinical updates and practical guidance.

Authors:  Jun Ho Yi; Seok Jin Kim; Won Seog Kim
Journal:  Blood Res       Date:  2017-12-26

Review 10.  Epstein-Barr virus-associated lymphomas.

Authors:  Claire Shannon-Lowe; Alan B Rickinson; Andrew I Bell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-10-19       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.